Metrics cut 2
- CRAMS demerger and Vizag retrofitting plans: deferred/on hold until the Ibuprofen strategic review concludes in Q2 FY27 (prior timeline not stated)
- Ibuprofen capital recovery: full recovery of the ~₹700 crores deployed now considered farfetched; strategic review may involve a capital cut/shaving (prior full-recovery expectation not formalized)
Event Participants
Executives
3
Abhishek Singhal, Sandeep Rao, Sarat Kumar
Analysts
14
Abhay Amrutiya, Achuth, Akash Jain, Aman Chakraborty, Anand Mundra, Gautami Agarwal, Hiten, Japreet Singh, Neeraj Shah, Parth Mehta, Prince, Sajal Kapoor, Shashwat Singh, Zakir Naseer
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Revenue | ₹384 crores | +20% YoY; includes ~₹30 crores of cost pass-through; ~flat QoQ on adjusted basis |
| Base Business Revenue | ₹307 crores | +24% YoY; ~18–19% YoY excluding pass-through; second consecutive quarter above ₹300 crores |
| Base Business Gross Margin | 51.3% (₹158 crores) | +10% YoY in absolute terms; ~54.5% adjusted for ₹17–18 crores pass-through, within historical 52–55% range |
| Base Business EBITDA | ₹72 crores | +8% YoY; supported by 52%+ gross margin and operating cost leverage |
| Consolidated EBITDA | ₹63.5 crores | +10% YoY; margin 17%, +80 bps QoQ; highest in 18 quarters |
| PAT | ₹16.3 crores | +55% YoY; highest in 18 quarters |
| Ibuprofen EBITDA Margin | Negative 12% | Continued commodity pressure; marginal sequential improvement; expected quarterly loss run-rate ₹10–15 crores |
| Net Debt | ₹479 crores | Down ₹135 crores (22%) in Q1; ₹100 crores from rights issue proceeds, ₹35 crores from operations |
| Net Debt/EBITDA | 1.9x | On annualized Q1 EBITDA; expected to improve to ~1.7x with net debt ~₹440 crores by Mar-27 |
Geographic & Segment Commentary
Base Business: Revenues at ₹307 crores, up 24% YoY (18–19% ex pass-through); gross margin 51.3% reported, ~54.5% adjusted; EBITDA ₹72 crores, up 8% YoY. Growth driven by debottlenecking high-margin products, geographic expansion into new markets, and new business wins. Operates from Cuddalore, Bangalore, and Ambernath at ~70% capacity utilization; management confident of sustaining at least 10% YoY growth.
Ibuprofen (Commodity) Business: Reported negative 12% EBITDA margin amid West Asia-led solvent shortages and input cost inflation. Top line held due to price increases, but volumes declined; ~₹700 crores capital deployed. Strategic review on track for H1 FY27; management expects a ₹10–15 crores quarterly EBITDA loss run-rate.
CRAMS / Vizag Facility: CRAMS demerger and Vizag retrofitting plans are on hold until the strategic review concludes in Q2 FY27. Vizag remains mothballed and is not currently used for either the base business or CRAMS.
Company-Specific & Strategic Commentary
Ibuprofen Strategic Review: On track for resolution in H1 FY27; management is evaluating options and will provide clarity with Q2 results. Full recovery of the ~₹700 crores deployed capital is considered "farfetched"; decisions could be reconsidered only if the business becomes value-accretive.
Deleveraging: Net debt reduced 22% in Q1 to ₹479 crores, aided by rights issue proceeds and operational cash flows. Target of sub-₹450 crores by March 2027; internal aspiration of net debt-free by FY29.
Capex & Debottlenecking: FY27 capex of ₹55–60 crores, with ~₹40 crores toward debottlenecking high-margin product lines and ₹10–15 crores maintenance. No greenfield; debottlenecking expected to expand capacity 20–30% with payback in 2–3 quarters.
Working Capital & S&OP: Working capital optimization remains a key priority; S&OP planning is expected to improve inventory norms rather than cede efficiency for growth.
Operational Priorities: Three levers for the next phase – expanding existing business and seeding new businesses, driving operational efficiency via debottlenecking, and prudent working capital management.
US Tariffs: Recent US tariff announcement has no implementing framework or product scope clarity yet; management awaiting formal policy details before assessing impact on API exports.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Base Business Revenue Growth | ≥10% YoY (FY27) | Currently running higher; driven by debottlenecking and geographic expansion (Sarat Kumar) |
| Base Business EBITDA Margin | 25% ±1% (FY27) | Sustained by 52–55% gross margins and operating cost discipline (Sarat Kumar) |
| Base Business Gross Margin | 52–55% | Product-mix dependent; aspiration to remain close to 55% (Sandeep Rao) |
| Net Debt | Sub ₹450 crores (~₹440 crores) by Mar-27; net debt-free by FY29 | Based on scheduled repayments; net debt/EBITDA to improve to ~1.7x (Sarat Kumar) |
| Capex | FY27: ₹55–60 crores; FY28/29: ₹40–50 crores annually | Majority debottlenecking; no greenfield; payback 2–3 quarters (Sarat Kumar) |
| Ibuprofen EBITDA Loss | ₹10–15 crores per quarter | Commodity dynamics and solvent availability; strategic resolution expected H1 FY27 (Sarat Kumar) |
Risks & Constraints
| Risk | Context |
|---|---|
| West Asia Crisis / Raw Material Availability | Geopolitical tensions have driven up solvent/petroleum-based input costs and caused supply shortages, leading to intermittent production line shutdowns. Management has managed via transparent cost pass-through, but not all customers accept increases; risk remains outside management control. |
| Ibuprofen Commodity Losses | Business posted negative 12% EBITDA margin with ~₹700 crores capital deployed; strategic review may involve a capital "cut" or "shaving" and full recovery is considered unlikely. |
| US Tariff Uncertainty | Recent US tariff announcement lacks an implementing framework and product scope clarity; potential impact on API exports to regulated markets is yet to be assessed. |
| Demand Cyclicality & Product Mix | API industry Q1 offtake is seasonally lower; top 15–16 products contribute 75%+ of revenue, making quarterly performance mix-sensitive; YoY trends are considered more meaningful. |
| Turnaround Execution | Management cautions that a confirmed turnaround requires 3–4 consistent quarters of growth; limited working capital necessitates judicious deployment of every rupee. |
Q&A Highlights
Strategic Priorities & Turnaround Levers
- Question: What are the top 2–3 operational priorities for the next phase of Solara's turnaround? (Sajal Kapoor, Antifragile Thinking)
- Answer: Sandeep Rao outlined three levers – expanding existing business and seeding new businesses, driving operational efficiency through debottlenecking existing capacity (no greenfield), and optimizing working capital to fund growth.
Ibuprofen Strategic Review & Capital Recovery
- Question: Are you still comfortable with the Q2 FY27 timeline for the Ibuprofen strategic review? Any milestones? (Sajal Kapoor; similar from Neeraj Shah)
- Answer: Sandeep Rao confirmed the company is on track for H1 FY27 resolution and will provide clarity with Q2 results; Sarat Kumar added that expecting full capital recovery is "farfetched." On reconsidering the exit if prices improve, Sandeep noted decisions can be revisited if value-accretive, but ibuprofen's commodity dynamics are unlikely to change.
Revenue Growth Composition & Gross Margin Volatility
- Question: Why have gross margins been volatile? How much of growth was volume vs price, and can you pass on cost increases? (Akash Jain, Moneycurves Analytics)
- Answer: Sarat Kumar attributed ~₹30 crores of consolidated revenue to cost pass-through; adjusted consolidated gross margin is ~53%. Base business pass-through was ₹17–18 crores, with adjusted gross margin of ~54.5% vs reported 51.3%. Sandeep Rao stated gross margins are comfortable in the 50–55% range, with aspiration near 55%; most customers accepted price increases due to transparency, though not all increases can be clawed back.
Base Business Growth Sustainability & Seasonality
- Question: What drove 24% base business growth, and is it sustainable? Also, revenue appears flat QoQ – any demand normalization issues? (Shashwat Singh, Bajaj; Aman Chakraborty, AK Investment)
- Answer: Sarat Kumar cited debottlenecking of high-margin products and geographic expansion as key drivers; adjusted growth is 18–19% YoY, and management is confident of at least 10% YoY growth going forward. He explained API industry seasonality (lower Q1, higher Q4) and product-mix effects; Sandeep Rao noted base revenue has reached a new plateau of ₹300+ crores in the last two quarters.
Deleveraging, Working Capital & Capital Allocation
- Question: Do you continue being debt-free by 2029? Can strong cash generation accelerate it? (Gautami Agarwal, Individual Investor)
- Answer: Sarat Kumar said net debt-free by FY29 is an internal aspiration, not a formal outlook.
- Question: Is current working capital efficiency sustainable as revenues scale? What is the capital allocation plan? (Sajal Kapoor)
- Answer: Sarat Kumar expects working capital efficiency to hold or improve through S&OP planning. Capex will be ₹55–60 crores in FY27 (mostly debottlenecking) and ₹40–50 crores annually in FY28/29; no greenfield, with debottlenecking payback in 2–3 quarters.
Capacity Utilization & Vizag
- Question: What is base business capacity utilization and the status of Vizag? (Akash Jain)
- Answer: Sarat Kumar stated average utilization across Cuddalore, Bangalore, and Ambernath is ~70%. Vizag remains mothballed; the CRAMS retrofit and demerger plans are on hold until the Q2 strategic review outcome.
Macro Risks: West Asia Crisis & US Tariffs
- Question: What is the impact of fuel cost volatility and US tariffs? (Parth Mehta, Antique Stock Broking)
- Answer: Sarat Kumar noted solvent/petroleum-based raw material costs and supply challenges persist, but absolute gross margins are being protected via pass-through. Sandeep Rao said US tariffs are only an "intent" announcement with no legal framework; the company awaits product scope clarity.
- Question: What risks could derail the turnaround over the next 12–24 months? (Abhay Amrutiya, Credence Wealth)
- Answer: Sandeep Rao identified the West Asia crisis as the foremost risk – raw material availability causing intermittent shutdowns and partial price acceptance – and stressed it is outside management control.
Key Takeaway
Solara Active Pharma Sciences delivered its strongest quarter in 18 quarters, with consolidated revenue of ₹384 crores (+20% YoY), EBITDA of ₹63.5 crores (17% margin, +80 bps QoQ) and PAT of ₹16.3 crores (+55% YoY). The base business reached a revenue plateau of ₹307 crores (+24% YoY) on debottlenecking and geographic expansion, while Ibuprofen remained a drag with a negative 12% EBITDA margin. Deleveraging accelerated – net debt fell 22% to ₹479 crores, aided by rights issue proceeds – with a target of sub-₹450 crores by March 2027 and net debt-free status by FY29. Management guides base business growth of at least 10% YoY with ~25% EBITDA margin, and FY27 capex of ₹55–60 crores focused on debottlenecking. Key watch points include the Ibuprofen strategic review resolution by H1 FY27, persistence of West Asia-led input cost pressures, and US tariff policy clarity.